scholarly journals Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients

2016 ◽  
Vol 20 (3) ◽  
pp. 407-415 ◽  
Author(s):  
Akihito Kawazoe ◽  
Takeshi Kuwata ◽  
Yasutoshi Kuboki ◽  
Kohei Shitara ◽  
Akiko Kawano Nagatsuma ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Mismatch Repair ◽  
Epstein Barr Virus ◽  
Clinicopathological Features ◽  
Programmed Death Ligand 1 ◽  
Barr Virus ◽  
Programmed Death ◽  
Epstein Barr ◽  
Gastric Cancer Patients

Clinicopathological features of program death ligand-1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 4040-4040 ◽  
Author(s):  
Akihito Kawazoe ◽  
Kohei Shitara ◽  
Yasutoshi Kuboki ◽  
Hideaki Bando ◽  
Takashi Kojima ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mismatch Repair ◽  
Epstein Barr Virus ◽  
Metastatic Gastric Cancer ◽  
Cancer Genome ◽  
Clinicopathological Features ◽  
Barr Virus ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Epstein Barr

4040 Background: Recently, anti-programmed death 1 (PD-1) or its ligand (PD-L1) antibodies have shown promising activities in metastatic gastric cancer (MGC). However, little is known about detailed clinicopathological features of PD-L1 expression in patients (pts) with MGC. Methods: Pts with histologically confirmed MGC were eligible for this prospective observational study. PD-L1 expression on tumor cell (TC) or inflammatory cell (IC) and mismatch repair (MMR) were analyzed by immunohistochemistry (IHC). Epstein–Barr virus (EBV) was detected by in situ hybridization. The expressions of tyrosine kinase receptors (RTKs) such as HER2, EGFR and MET and cancer genome alterations were also evaluated by IHC or next generation sequencing. Results: A total of 237 pts were enrolled from September 2015 to December 2016. Samples of 199 (84.0%) pts were obtained from biopsy. PD-L1 expression on TC and IC was positive in 27 (11.4%) and 167 pts (70.5%), respectively. One hundred and seventy-one pts (72.2%) had positive PD-L1 expression on either TC or IC. MMR deficient (D-MMR) and EBV was detected in 14 (6.9%, n = 203) and 14 pts (5.9%, n = 237), respectively. PD-L1 expression on TC was more frequently observed in pts with D-MMR (P < 0.001) and KRAS mutation (P < 0.001), while that on IC was more frequently observed in pts with EBV+ (P = 0.045), lymph node metastasis (P = 0.001), and lung metastasis (P = 0.045). In contrast, pts with peritoneal metastasis were associated with less frequent PD-L1 expression in IC (P = 0.003). A significant association was not observed between PD-L1 expression and RTKs expression or presence of other gene alterations. D-MMR was significantly associated with intestinal type (P = 0.026) and absence of liver metastasis (P = 0.022). PD-L1 expression on either TC or IC was not prognostic factor (hazard ratio; 0.92, P = 0.741). Seven pts with D-MMR and seven pts with EBV+ MGC were enrolled in clinical trials of anti-PD-1/PD-L1 antibodies. Conclusions: PD-L1 expression in MGC was associated with some clinicopathological features. Impact of these characteristics on efficacy of anti-PD-1/PD-L1 antibody warrants further evaluation.

scholarly journals Association between Epstein-Barr Virus Infection and Gastric Cancer: A Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Ahmad Tavakoli ◽  
Seyed Hamidreza Monavari ◽  
Farid Solaymani Mohammadi ◽  
Seyed Jalal Kiani ◽  
Saber Armat ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Epstein Barr Virus ◽  
The Body ◽  
Matched Pairs ◽  
Barr Virus ◽  
Ebv Infection ◽  
Analytic Review ◽  
Epstein Barr ◽  
Gastric Cancer Patients

Abstract Background: Numerous studies conducted over the past 30 years have pointed to the presence of Epstein–Barr virus (EBV) in gastric cancer samples. This study was aimed to provide a meta-analytic review of the prevalence of EBV in gastric cancer patients, and to clarify the relationship between EBV infection and gastric cancer. Methods: A literature search was performed electronically using online databases for English language publications until July 1, 2019. The pooled EBV prevalence and 95% confidence intervals (CIs) were estimated using a random effects model. To determine the association between EBV and gastric cancer, pooled odds ratio (OR) and its 95% CI were computed for case-control studies with matched pairs design. Results: The pooled prevalence of EBV in 20411 gastric cancer patients was 8.78% (95% CI: 7.75-9.93%; I 2 =83.0%). The proportion of EBV-associated gastric cancer among male cases was significantly higher than among female cases (10.85%, vs 5.72%) ( P <0.01). EBV was more prevalent in the cardia (12.47%) and in the body (11.68%) compared to the antrum (6.29%) ( P <0.01). There were 20 studies with matched pairs design, including tumor and tumor-adjacent normal tissue pairs from 4116 gastric cancer patients. The pooled OR between EBV infection and gastric cancer risk was 18.56 (95% CI: 15.68–21.97; I 2 = 55.4%). Conclusion: EBV infection is associated with more than 18 times increase risk of gastric cancer. Although the prevalence of EBV was higher in male patients than in female patients with gastric cancer, women are more likely than men to develop EBV-associated gastric cancer.

scholarly journals Association between Epstein-Barr Virus Infection and Gastric Cancer: A Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Ahmad Tavakoli ◽  
Seyed Hamidreza Monavari ◽  
Farid Solaymani Mohammadi ◽  
Seyed Jalal Kiani ◽  
Saber Armat ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Epstein Barr Virus ◽  
The Body ◽  
Matched Pairs ◽  
Barr Virus ◽  
Ebv Infection ◽  
Analytic Review ◽  
Epstein Barr ◽  
Gastric Cancer Patients

Abstract Background: Numerous studies conducted over the past 30 years have pointed to the presence of Epstein–Barr virus (EBV) in gastric cancer samples. This study was aimed to provide a meta-analytic review of the prevalence of EBV in gastric cancer patients, and to clarify the relationship between EBV infection and gastric cancer. Methods: A literature search was performed electronically using online databases for English language publications until July 1, 2019. The pooled EBV prevalence and 95% confidence intervals (CIs) were estimated using a random-effects model. To determine the association between EBV and gastric cancer, pooled odds ratio (OR) and its 95% CI were computed for case-control studies with matched pairs design. Results: The pooled prevalence of EBV in 20411 gastric cancer patients was 8.78% (95% CI: 7.75-9.93%; I 2 =83.0%). The proportion of EBV-associated gastric cancer among male cases was significantly higher than among female cases (10.85%, vs. 5.72%) ( P <0.01). EBV was more prevalent in the cardia (12.47%) and the body (11.68%) compared to the antrum (6.29%) ( P <0.01). There were 20 studies with matched pairs design, including tumor and tumor-adjacent normal tissue pairs from 4116 gastric cancer patients. The pooled OR between EBV infection and gastric cancer risk was 18.56 (95% CI: 15.68–21.97; I 2 = 55.4%). Conclusions: EBV infection is associated with more than 18 times increase the risk of gastric cancer. Although the prevalence of EBV was higher in male patients than in female patients with gastric cancer, women are more likely than men to develop EBV-associated gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document